Invion (AU:IVX) has released an update.
Invion Limited has appointed Professor Robert Ramsay, a leading expert in cancer biology, as its Scientific Advisor to guide its clinical trials and research programs. Ramsay’s expertise, particularly with Invion’s lead cancer drug candidate INV043, is expected to enhance the company’s efforts in advancing Photodynamic Therapy for cancer treatment. This strategic move aligns with Invion’s mission to develop life-changing therapies and address unmet needs in patient care.
For further insights into AU:IVX stock, check out TipRanks’ Stock Analysis page.